MX2021009383A - Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. - Google Patents
Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.Info
- Publication number
- MX2021009383A MX2021009383A MX2021009383A MX2021009383A MX2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lysosomal storage
- storage diseases
- disorders associated
- treating symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800996P | 2019-02-04 | 2019-02-04 | |
| US201962851433P | 2019-05-22 | 2019-05-22 | |
| US201962894167P | 2019-08-30 | 2019-08-30 | |
| US201962937618P | 2019-11-19 | 2019-11-19 | |
| US202062962647P | 2020-01-17 | 2020-01-17 | |
| PCT/US2020/016441 WO2020163245A1 (en) | 2019-02-04 | 2020-02-03 | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009383A true MX2021009383A (es) | 2021-09-10 |
Family
ID=69743942
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009383A MX2021009383A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
| MX2021009384A MX2021009384A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009384A MX2021009384A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
Country Status (13)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| PT3920912T (pt) | 2019-02-04 | 2025-09-09 | Genzyme Corp | Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs) |
| IL295255A (en) | 2020-02-03 | 2022-10-01 | Genzyme Corp | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| IL300090A (en) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Pharmaceutical preparations containing VENGLUSTAT |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (cg-RX-API-DMAC7.html) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| LT2685986T (lt) * | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
| AU2012272815B2 (en) * | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| JO3713B1 (ar) * | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| EP3079695B1 (en) | 2013-12-11 | 2021-03-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
-
2020
- 2020-02-03 SG SG11202107844UA patent/SG11202107844UA/en unknown
- 2020-02-03 MX MX2021009383A patent/MX2021009383A/es unknown
- 2020-02-03 WO PCT/US2020/016440 patent/WO2020163244A1/en not_active Ceased
- 2020-02-03 AU AU2020217659A patent/AU2020217659B2/en active Active
- 2020-02-03 KR KR1020217027945A patent/KR20210123352A/ko not_active Ceased
- 2020-02-03 IL IL313808A patent/IL313808B1/en unknown
- 2020-02-03 CN CN202080025346.0A patent/CN113645969A/zh active Pending
- 2020-02-03 US US17/428,505 patent/US20220016092A1/en active Pending
- 2020-02-03 IL IL285304A patent/IL285304B2/en unknown
- 2020-02-03 EP EP20709405.3A patent/EP3920913A1/en active Pending
- 2020-02-03 WO PCT/US2020/016441 patent/WO2020163245A1/en not_active Ceased
- 2020-02-03 CA CA3128039A patent/CA3128039A1/en active Pending
- 2020-02-03 BR BR112021015099-4A patent/BR112021015099A2/pt unknown
- 2020-02-03 SG SG11202107842QA patent/SG11202107842QA/en unknown
- 2020-02-03 EP EP20709406.1A patent/EP3920914A1/en active Pending
- 2020-02-03 BR BR112021015172-9A patent/BR112021015172A2/pt unknown
- 2020-02-03 IL IL285187A patent/IL285187B1/en unknown
- 2020-02-03 KR KR1020217027946A patent/KR20210123353A/ko not_active Ceased
- 2020-02-03 CN CN202080025266.5A patent/CN113710249A/zh active Pending
- 2020-02-03 MX MX2021009384A patent/MX2021009384A/es unknown
- 2020-02-03 AU AU2020218496A patent/AU2020218496B2/en active Active
- 2020-02-03 US US17/428,504 patent/US20220023273A1/en active Pending
- 2020-02-03 JP JP2021545375A patent/JP2022520747A/ja active Pending
- 2020-02-03 JP JP2021545383A patent/JP7511567B2/ja active Active
- 2020-02-04 TW TW109103397A patent/TWI865485B/zh active
- 2020-02-04 TW TW113119270A patent/TW202508582A/zh unknown
-
2025
- 2025-02-07 JP JP2025018867A patent/JP2025072556A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007592A (es) | Compuestos macrociclicos y su uso en el tratamiento de enfermedades. | |
| BR112013031510A2 (pt) | [1,3]oxazinas | |
| EA201290519A1 (ru) | Положительные аллостерические модуляторы рецептора хинолин амида m1 | |
| MX2012001985A (es) | Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina. | |
| TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
| NI201100100A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
| NZ602777A (en) | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
| UA96447C2 (ru) | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы | |
| PH12021553248A1 (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| MX2013008478A (es) | 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2). | |
| BR112014015630A2 (pt) | fluorometil-5,6-di-hidro-4h-[1,3]oxazinas | |
| BR112016015763B8 (pt) | preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma | |
| MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
| JOP20240081A1 (ar) | مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها | |
| WO2020219486A9 (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof |